Ownership history in Column Group LLC Β· 18 quarters on record
This page tracks every 13F SEC filing in which Column Group LLC reported a position in Tenaya Therapeutics, Inc. (TNYA). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Column Group LLC underperformed the S&P 500 by β24.4% annually on this TNYA position. Average cost basis: $20.65. Maximum drawdown during holding period: β97.2%.
β Significantly underperformed the S&P 500 by 24.4% ann.
17 quarters analyzed
Best entry: $20.65 (2021 Q3) Β· Worst: $20.65 (2021 Q3)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
1 add Β· 0 trims. Bought during 0 of 11 down-price quarters. π Consistently bullish β fund kept accumulating this position.
π Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 8.08% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size